 CAMBRIDGE, United Kingdom and SHANGHAI, China, April 12, 2021 GLOBE NEWSWIRE -- Abcam AIM: ABC; NASDAQ: ABCM, a global innovator in life science reagents and tools, and MEDx Translational Medicine MEDx, formerly QIAGEN Suzhou Translational Medicine Co., Ltd., a company dedicated to developing companion diagnostics and precision medicine, announced the extension of their strategic partnership to include the co-development and commercialization of key companion and in vitro diagnostic kits for MEDx to supply to the Chinese market. 